Addition of Lenalidomide to Melphalan in the Treatment of Newly Diagnosed Multiple Myeloma: The National Cancer Institute of Canada Clinical Trials Group MY.11 Trial

Oral melphalan and prednisone remain an effective and tolerable treatment for patients with multiple myeloma. For approximately 40 years, this combination has been the standard of care for patients not proceeding to stem cell transplant. Within the last 10 years, new agents have been found to be efficacious in the relapsed/refractory setting. Within the last year, two trials of added thalidomide in the newly diagnosed setting have demonstrated …